Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. - Wikidata - wikimedia - TriplyDB

Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer.

Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer.

http://www.wikidata.org/entity/Q42450903

about

Epimutation and cancer: a new carcinogenic mechanism of Lynch syndrome (Review)BRCA1 is a negative modulator of the PRC2 complex 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers Understanding and treating triple-negative breast cancer Comprehensive molecular portraits of human breast tumours A de novo complete BRCA1 gene deletion identified in a Spanish woman with early bilateral breast cancer Risk factors for triple-negative breast cancer in women under the age of 45 years High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families.Relationship of patients' age to histopathological features of breast tumours in BRCA1 and BRCA2 and mutation-negative breast cancer families.Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer Cancer stem cell metabolism Biomarkers in triple negative breast cancer: A review The fate of chemoresistance in triple negative breast cancer (TNBC)Oncogenes induce the cancer-associated fibroblast phenotype: metabolic symbiosis and "fibroblast addiction" are new therapeutic targets for drug discovery A perspective on anti-EGFR therapies targeting triple-negative breast cancer On metabolic reprogramming and tumor biology: A comprehensive survey of metabolism in breast cancer Is it time to split strategies to treat homologous recombinant deficiency in pancreas cancer?Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins The "portrait" of hereditary breast cancer Pathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutations Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer Breast cancer subtypes and previously established genetic risk factors: a bayesian approach The epigenetic modifier JMJD6 is amplified in mammary tumors and cooperates with c-Myc to enhance cellular transformation, tumor progression, and metastasis Breast cancer classification and prognostication through diverse systems along with recent emerging findings in this respect; the dawn of new perspectives in the clinical applications.Reproductive factors and risk of contralateral breast cancer by BRCA1 and BRCA2 mutation status: results from the WECARE study Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study.A role for the TGFbeta-Par6 polarity pathway in breast cancer progression Expression of Nestin associates with BRCA1 mutations, a basal-like phenotype and aggressive breast cancer.Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status.Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger.Use of immunohistochemical markers can refine prognosis in triple negative breast cancer.EGFR associated expression profiles vary with breast tumor subtype Expression of estrogen receptor beta in the breast carcinoma of BRCA1 mutation carriers The UPS: a promising target for breast cancer treatment.Carboplatin and gemcitabine combination in metastatic triple-negative anthracycline- and taxane-pretreated breast cancer patients: a phase II study.The prevalence of BRCA1 mutations among young women with triple-negative breast cancer.Efficacy of carboplatin-based preoperative chemotherapy for triple-negative breast cancer. A meta-analysis of randomized controlled trials The ordering of expression among a few genes can provide simple cancer biomarkers and signal BRCA1 mutations.Current data of targeted therapies for the treatment of triple-negative advanced breast cancer: empiricism or evidence-based?

P2860

Q22255392-62CD1B0B-929D-496C-AFDD-E802E480656B Q24339430-604C39AF-C99C-478A-B061-2258938ED770 Q24600350-DF611A2B-0B92-4941-8D47-916646056987 Q24620957-2D088826-1265-4D40-A998-B2DB3A2B0F25 Q24630844-EC26768C-5A92-4EE9-944F-DAFC1583DE26 Q24632225-0F9B5301-B9BA-41F1-B33A-81F4A4695A36 Q24644075-CE62A7C0-4711-4528-B1D5-D6259F73C218 Q24644255-A9E76295-380B-40B3-AA1E-6CF5AC0F449B Q24796660-3B5E413C-C88D-4A7B-9AC1-52F455C05D86 Q24810584-18758629-D7D8-4C1F-A363-EC3AE655A1F4 Q24810751-9AE44A33-A5BE-4B39-BF69-FFF05AA7F22A Q26746123-43728972-9A77-4FE0-8DB5-8EBDDC6066F9 Q26775094-C700F06D-E870-4FE7-9CCE-F1122E15F5DE Q26775232-559CEA85-01AE-4C3D-AB3D-11DD8ED105EE Q26851813-8F70C6C6-5AD1-4F79-AFBF-0E8768D5A23C Q28069867-1B46EDF6-04EC-4CAA-A741-04DEB6B1BA22 Q28072798-D44C8D94-8033-427D-87C5-926C6387A348 Q28073673-6169D29A-D8C4-4971-BC62-C5D1DD41B573 Q28085364-27D6E877-F550-44BF-AA25-98C64FCEDE8D Q28238725-900BFA9D-396B-4CE6-AA9D-9981E5469E20 Q28265304-42E505FE-B9A5-4775-9D1C-066FC9E3CD11 Q28372484-B6804B11-2990-468C-9C8A-E5D73E24434E Q28397311-238A07E7-2ABA-4AFF-94B3-E7ED849DC5AC Q29544441-D415D1A6-AEFB-4C76-A4BF-7C5C4E837F84 Q30245184-C6DE1BA5-A046-4872-8AAB-799D582AD803 Q30432062-BBEF42AF-0FEF-4296-8F59-63123A4EF8E6 Q30433319-C724B7E1-B774-4FB9-9C7F-1ACAF1749B62 Q30489618-7C935AC7-EA2F-4032-875C-2C03E087A9F5 Q30491493-4E26E51D-C5DC-416D-8052-43EA042235F8 Q30496322-7974721F-37E8-4DA7-9192-1C904FAD1662 Q30541773-E1425E7B-2FBB-4DBD-B49F-721751209E66 Q33291587-12D75588-2037-4679-A9B9-0947841FB9F2 Q33292502-D6C4D8D8-9463-4B51-8FE7-9B9C60D6D02B Q33327785-FCBCB68C-DEF4-468F-BCAF-6F32AE460A6B Q33384289-DF3767F3-3E5B-4FCF-9B9B-E2FBA38092F7 Q33394861-8241C513-31FF-4FB1-BC9E-D072D774AD56 Q33419708-3031E529-8F84-4E64-9E7F-3EA3AC28FDED Q33438050-F49F5905-953B-427C-9185-2F0CC1C7A01F Q33495401-12987678-B9CE-434A-8C27-B2E9D421ED9D Q33500786-94E8F3B8-E320-4CE9-A74C-C5FF042243F6

P2860

Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer.

http://www.wikidata.org/entity/Q42450903

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

2003年论文

@zh

2003年论文

@zh-cn

name

Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer.

@en

Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer.

@nl

type

label

Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer.

@en

Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer.

@nl

prefLabel

Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer.

@en

Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer.

@nl

P1433

Q42450903-29B9D296-893B-4446-9F2E-24B80C4F06A4

P1476

Q42450903-B1922040-3594-4B53-8851-35DC36C0CFAC

P2093

Q42450903-0BE65C02-3B76-442D-86EA-E2B6C30E9B69

Q42450903-4695CDC8-AF0E-4029-B5C7-AA08264C216C

Q42450903-61677928-FD11-48B5-B6C1-F90AF3B8DD78

Q42450903-854502A6-F75D-47A0-ABA5-F930668FEAD1

Q42450903-B6A6A80A-20E3-42A6-AE5C-922FE691C316

Q42450903-C84767B6-BB24-455F-80EB-DCB63ABF030E

P304

Q42450903-F3450B55-B3D3-44D5-93FE-B4371BB1449A

P31

Q42450903-2C4A69F0-9D54-49AE-A4EF-C41DF4AC357B

P356

Q42450903-E631366B-AB04-4FC2-A464-FF7B223A3B8E

P407

Q42450903-6B19E18F-52C7-4B42-A882-3F4BF52D5BD0

P433

Q42450903-2C82C256-8006-41C3-97E8-6D2EB3A4CF30

P478

Q42450903-547C5A7E-C83A-4543-89BE-9BBF78652915

P50

Q42450903-0DF6E2FF-1D9A-42F1-916F-EA389D80E40E

Q42450903-0FFDBE6C-8DE2-4907-8140-4571D9C52A10

P577

Q42450903-9091B979-40D9-4E5E-8AC7-88085F9A0AE9

P698

Q42450903-665170A1-15A2-4019-94FA-202B42D32613

P356

P1433

Journal of the National Cancer Institute

P1476

Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer.

@en

P2093

Ingunn M Stefansson

http://www.w3.org/2001/XMLSchema#string

John R Goffin

http://www.w3.org/2001/XMLSchema#string

Louis R Bégin

http://www.w3.org/2001/XMLSchema#string

Michel Trudel

http://www.w3.org/2001/XMLSchema#string

Nora Wong

http://www.w3.org/2001/XMLSchema#string

Pierre O Chappuis

http://www.w3.org/2001/XMLSchema#string

P304

1482-1485

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNCI/DJG050

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

95

http://www.w3.org/2001/XMLSchema#string

P50

William D Foulkes

P577

2003-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

14519755

http://www.w3.org/2001/XMLSchema#string